Drug-resistant variants of thymidylate synthase (TS) can potentially be used in gene therapy applications to decrease the myelosuppressive side effects of TS-directed anticancer agents or to select genetically modified cells in vivo. Mutations of proline 303 of human TS confer resistance to TS-directed fluoropyrimidines and antifolates (Kitchens et al., 1999) . We generated the corresponding variants in Escherichia coli TS (ecTS), position 254, to better understand the mechanism by which mutations at this residue confer resistance. In addition, because ecTS is intrinsically resistant to several antifolates when compared with human TS, we suspected that greater resistance could be achieved with the bacterial enzyme. The P254L enzyme conferred Ͼ100-fold resistance to both raltitrexed and 5-fluoro-2Ј-deoxyuridine (FdUrd) compared with wild-type ecTS. Four additional mutants (P254F, P254S, P254G, and P254D), each of which complemented growth of a TS-deficient cell line, were generated, isolated, and characterized. Steady-state values of K m for dUMP and k cat were not substantially different among the variants and were comparable with the wild-type values, but K m for methylenetetrahydrofolate (CH 2 H 4 PteGlu) was Ͼ10-fold higher for P254D. Values of k on and k off for nucleotide binding, which were obtained by stopped-flow spectroscopy, were virtually unchanged among the mutants. Drastic differences were observed for CH 2 H 4 PteGlu binding, with K d values Ͼ15-fold higher than observed with the wild-type enzyme; surprisingly, the proposed isomerization reaction that is very evident for the wild-type enzyme is not observed with P254S. The decrease in affinity for CH 2 H 4 PteGlu correlates well with K i values obtained for three TS-directed inhibitors. These results show that mutations at Pro-254 specifically affect the initial binding interactions between enzyme and cofactor and also alter the ability of the mutant enzymes to undergo conformational changes that occur on ternary complex formation. The crystal structure of P254S was determined at 1.5 Å resolution and is the most precise structure of TS available. When compared with wild-type TS, the structure shows local conformational changes affecting mostly Asp-253; its carbonyl is rotated approximately 40°, and the side chain forms an ion pair with Arg-225.
(CH 2 H 4 PteGlu) was Ͼ10-fold higher for P254D. Values of k on and k off for nucleotide binding, which were obtained by stopped-flow spectroscopy, were virtually unchanged among the mutants. Drastic differences were observed for CH 2 H 4 PteGlu binding, with K d values Ͼ15-fold higher than observed with the wild-type enzyme; surprisingly, the proposed isomerization reaction that is very evident for the wild-type enzyme is not observed with P254S. The decrease in affinity for CH 2 H 4 PteGlu correlates well with K i values obtained for three TS-directed inhibitors. These results show that mutations at Pro-254 specifically affect the initial binding interactions between enzyme and cofactor and also alter the ability of the mutant enzymes to undergo conformational changes that occur on ternary complex formation. The crystal structure of P254S was determined at 1.5 Å resolution and is the most precise structure of TS available. When compared with wild-type TS, the structure shows local conformational changes affecting mostly Asp-253; its carbonyl is rotated approximately 40°, and the side chain forms an ion pair with Arg-225.
Effective drug treatment of human malignancies can be hampered by myelosuppressive side effects that result in increased susceptibility to life-threatening infections. The understanding of the molecular events leading to drug resistance has allowed investigators to test the feasibility of transferring genes that confer such resistance into normal cells. Gene transfer of chemoprotecting genes into bone marrow cells has the potential of protecting multiple hematopoietic lineages from the deleterious effects of chemotherapy, thereby allowing more aggressive chemotherapeutic dosing (reviewed in Koc et al., 1996) . In addition to attenuating myelosuppression, genes that confer chemoprotection can provide a selective advantage to genetically modified hematopoietic cells. Studies using gene transfer of the cDNA that encodes MDR-1 or dihydrofolate reductase (DHFR) provide evidence that selectable markers can be used for in vivo enrichment of gene-modified cells (Sorrentino et al., 1992; Spencer et al., 1996; Allay et al., 1998) .
Although the use of MDR-1 and DHFR have advanced to clinical trials (Hesdorffer et al., 1994; O'Shaughnessy et al., 1994; Deisseroth et al., 1996) , there is a need to adapt such technologies to the attenuation of side effects of other important neoplastic agents. Thymidylate synthase (TS) is an excellent candidate for drug-resistant gene therapy, because it is a pre-eminent target for the design of new anticancer agents [e.g., raltitrexed (Tomudex) and BW1843U89]. In addition, it is the target of mainstream chemotherapy agents (e.g., 5-FU); the recombinant enzyme has been well-characterized, and the cDNA that encodes TS is relatively small (Ͻ1,000 base pairs) (Davisson et al., 1989; Carreras and Santi, 1995; Reilly et al., 1995; Touroutoglou and Pazdur, 1996; Spencer et al., 1997) .
TS catalyzes the transfer of a methyl group from methylenetetrahydrofolate (CH 2 H 4 PteGlu) to dUMP, forming TMP. Inhibition of TS results in apoptotic cell death that is caused by intracellular thymidine depletion. Acquired resistance to TS inhibitors is a multifactorial process that can include amplification and/or mutation of the TS gene. In cells adapted to high concentrations of FdUrd, we showed that TS gene amplification in addition to mRNA and enzyme overproduction were commonly observed (Kitchens et al., 1999) . For some adapted cell lines, overproduction of mRNA and protein were discordant, indicating that post-transcriptional mechanisms are involved in the resistance phenotype. A Pro to Leu substitution at residue 303 of human TS was identified and shown to be the effector of 5-fluoro-2Ј-deoxyuridine (FdUrd) resistance.
Crystal structures and rate constants governing individual steps in the catalytic mechanism of human TS are not available. Therefore, to better understand the mechanism by which mutations at residue 303 of human TS confer drug resistance, we generated the corresponding mutation in Escherichia coli TS (ecTS), which is structurally and kinetically well-characterized. In addition, because ecTS is intrinsically resistant to several TS-directed antifolates, it was anticipated that greater resistance could be achieved using the bacterial enzyme. Five amino acid substitutions were generated at residue 254, which is homologous to residue 303 of human TS, and steady-state and transient-state kinetic parameters were determined for each. The crystal structure of P254S TS was determined and used to explain its kinetic and mechanistic variations from the wild-type enzyme. The results show that mutations at Pro-254 decrease enzyme stability and decrease the affinity of the enzyme for CH 2 H 4 PteGlu and for three TS-directed antifolates but that the substitutions have little effect on nucleotide binding or the rate-limiting step of catalysis. The drastic decrease in antifolate affinity suggests that variants at residue 254 in ecTS may be suitable for use as drug-resistant markers in gene therapy applications.
Experimental Procedures
Site-Directed Mutagenesis and Growth Complementation Studies. The gene encoding ecTS, a gift from Dr. Dallas (Glaxo Wellcome, Research Triangle Park, NC), was amplified by polymerase chain reaction (PCR) to introduce XbaI and ClaI sites at the 5Ј-and 3Ј-ends of the coding region, respectively. The amplified sequence was cloned into the XbaI/ClaI sites of pBluescript SK (Stratagene, La Jolla, CA), which generated pBSecTS, transformed into XL-1 Blue bacterial cells, and sequenced to confirm the integrity of the ecTS gene. Mutations at residue 254 were produced by PCR mutagenesis using the overlap extension method to generate a 570-base pair product (Ho et al., 1989) . The PCR product was digested with NsiI and ClaI and cloned into the NsiI/ClaI sites of pBSecTS. The entire cloned region was sequenced to confirm the presence of the mutation and assure the absence of undesired mutations.
Plasmids encoding wild-type ecTS or the Pro-254 mutated enzymes were transformed into the tetracycline-resistant, rec A-deficient, TS-deficient bacterial strain, 2913. Transformed cells were grown in defined medium with tetracycline (selects for 2913 cells) and ampicillin (selects for transformed cells) but which lacked thymidine (selects for active TS mutants).
Protein Purification. Cell free extracts were obtained from 2 g of wet cells by five 30-s consecutive sonication cycles (Branson Sonifier 450; Danbury, CT) in 25 ml of degassed QA buffer (50 mM Tris, 14 mM 2-mercaptoethanol, and 1 mM EDTA, pH 7.5), centrifuged at 11,000g for 30 min, and applied to a DEAE Affi-Gel Blue (Sigma, St. Louis, MO) column (2.5 ϫ 15-cm) pre-equilibrated in QA buffer. The column was washed with three column volumes of QA buffer, two column volumes of 100 mM KCl, then by two column volumes of 200 mM KCl in QA buffer. Enzyme activity routinely eluted in 200 mM KCl. The eluted enzyme was dialyzed against QA buffer and applied to a 2.5 ϫ 20-cm Q-Sepharose FPLC column (Amersham Pharmacia Biotech, Piscataway, NJ) that had been equilibrated with degassed QA buffer. Elution was accomplished by using a 500-ml linear gradient of 200 to 600 mM KCl in QA buffer. Fractions were monitored for TS activity, which typically eluted between 360 and 420 mM KCl. Enzyme purity was assessed by SDS polyacrylamide gel electrophoresis, and purified proteins were stored in 15% glycerol at Ϫ70°C.
Kinetic Characterization of ecTS and Pro-254 VariantsSteady-State Determinations. The concentration of purified enzymes was determined using a molar extinction coefficient at 280 nm of 1.13 ϫ 10 5 M Ϫ1 cm Ϫ1 , and the number of binding sites was determined by FdUMP titration of protein absorbance at 330 nm. The concentrations of 1/2 binding sites were in good agreement with the concentrations determined by UV absorbance at 280 nm. The value of K m(dUMP) was determined using concentrations of dUMP between 1 and 100 M with 100 M CH 2 H 4 PteGlu, except 500 M CH 2 H 4 PteGlu was used for P254D. The value of K m(CH2H4PteGlu) was determined using CH 2 H 4 PteGlu concentrations in the range of 6 to 300 M in the presence of 100 M dUMP. Reactions were performed at 20°C in 100 mM Tris-HCl (pH 7.4), 1 mM EDTA, and 14 mM 2-mercaptoethanol, and activity was followed by measuring the absorbance at 340 nm. Velocity values were plotted versus the concentration of ligand, and the values of K m and k cat were determined using the program KaleidaGraph (Synergy Software, Reading, PA). Values of K i were determined using the program EZ-fit (Perrella Scientific, Amherst, NH) with enzyme concentrations ranging from 20 to 200 nM, dUMP concentrations of 100 M, and CH 2 H 4 PteGlu concentrations 3 times the K m values.
Kinetic Characterization of ecTS and Pro-254 VariantsTransient-State Determination. Ligand binding was followed on an Applied Photophysics (Surrey, UK) SX-18 stopped-flow fluorometer/spectrophotometer at 20°C in activation buffer (100 mM Tris buffer, pH 7.4, containing 10 mM 2-mercaptoethanol) using an excitation wavelength of 295 nm and emission wavelengths 330 nm as previously reported (Spencer et al., 1997) . Enzymes and ligands were diluted in activation buffer to concentrations 2 times that indicated within the text or in figure legends. After collection, data were computer-fitted by nonlinear least-squares analysis to equations describing single or multiple exponential terms using KaleidaGraph 3.0.1. At least five traces were averaged for every ligand concentration. The entire experiment for the determination of the association and dissociation rate constants was repeated a minimum of two times for each mutant.
Survival Curves. The cDNAs that encode wild type and P254L were cloned into the SacII/XhoI sites of the HaMSV retroviral vector (Sorrentino et al., 1992; Spencer et al., 1996) and transfected into the TS-deficient Chinese hamster lung cell line RJK88.13. Selection of transfected cells was accomplished by removing thymidine from the medium. Survival curves were generated by plating 40,000 cells/25-cm 2 flask with various concentrations of TS inhibitors. After 5 to 7 days, surviving cells were counted after trypan blue staining. At least three flasks were used for each concentration of drug.
Determination of Protein Levels-FdUMP Binding Assay. Extracts from Chinese hamster lung cells that contained ecTS constructs were prepared by sonication from two nearly confluent 100-mm dishes. Reaction mixtures contained, in 500 l, 50 g of cell free extract, 300 M CH 2 H 4 PteGlu, 100 l of Morrison buffer (120 mM Tris, 60 mM MES, 60 mM acetic acid, pH 7.2) and either 100 or 200 nM [ 3 H]FdUMP. Following 1 h of incubation at room temperature, 125 l of 50% trichloroacetic acid was added and centrifuged at 13,000g for 5 min. The pellet was washed four times with 10% trichloroacetic acid and resuspended in 2 N NaOH, 50% ethanol and counted. Concentrations of TS are expressed as picomoles of FdUMP bound per milligram of protein.
Crystallization of P254S TS. The purified enzyme was dialyzed against a buffer containing 1 mM EDTA, 10 mM 2-mercaptoethanol, 100 mM ammonium sulfate, and 20 mM potassium phosphate at pH 7.5 for 72 h. Crystals were grown using the vapor diffusion method in the hanging drop setup. Typically, 5 l of TS solution at 20 mg/ml was mixed with an equal volume of a precipitating well solution (58% saturated ammonium sulfate, 20 mM 2-mercaptoethanol, and 100 mM Tris-HCl, pH 8.8) and allowed to equilibrate with the well. Crystals appeared after 21 days and grew to the size of 0.4 mm within 1 week.
Crystallography. A crystal measuring approximately .4 ϫ .4 mm was transferred to a cryoprotectant solution and flash-frozen in liquid nitrogen. The data were collected at the SBC line of Advanced Photon Source at Argonne National Laboratory (Argonne, IL) using X-rays of 0.9793 Å in wavelength. Two sets of data were collected at high and low resolution with a 3 ϫ 3 CCD array detector, and were indexed, integrated, and scaled with the HKL 2000 suit of programs (Otwinowski and Minor, 1997) . The strategy option was used for collecting all possible independent reflections with minimum radiation damage to the crystal. In the first pass, oscillation frames were collected to record the high resolution data. The second pass was used to remeasure reflections that suffered from intensity overflow during the first pass. The detailed collection strategy is summarized in Table 5 . The structure of S167T mutant (unpublished data) with the appropriate amino acid sequence modifications was used as the starting model in molecular replacement using CCP4 software (Computational Collaborative Project, 1994) , and the data were optimized with the CNS software (Brunger et al., 1998 ) using positional and temperature refinements. Electron density maps calculated with 2F o Ϫ F c , and F o Ϫ F c coefficients were inspected to introduce corrections manually to the model with the interactive graphics program CHAIN (Sack and Quiocho, 1997) .
Results
Location of Pro-254. Pro-254 in ecTS is located at a bend 11 amino acids from the C-terminal isoleucine residue. Its side chain is not exposed to solvent but makes contact with the side chain of Arg-48. Figure 1 shows that the proline does not make direct contact with either bound nucleotide or folate (Hyatt et al., 1997) . However, the residue is situated in the middle of the final bend that directs the C-terminal residues toward the active site. The C-terminal residues, particularly the final four residues, are known to be crucial for CH 2 H 4 PteGlu binding.
Resistance Conferred by the P254L Mutant of ecTS. Substitution of leucine for proline at residue 303 of human TS confers resistance to fluoropyrimidines and antifolates (Kitchens et al., 1999) . To determine whether the homologous substitution in ecTS confers resistance, we engineered the corresponding mutation at residue 254 of ecTS. The cDNAs that encode wild-type ecTS or the P254L mutant were introduced into the HaMSV retroviral vector and transfected into the TS-deficient cell line RJK88.13. Both constructs complemented cell growth in media lacking thymidine, and transfected cells had similar levels of TS protein expression (1.2 pmol/mg of protein) as determined by radiolabeled FdUMP titrations and similar growth rates. Similar to human TS, but to a much greater extent, substitution of leucine for proline confers resistance to raltitrexed (Ͼ100-fold) and FdUrd (Ͼ500-fold) (Fig. 2) , indicating that ecTS is more sensitive to the Pro to Leu substitution than is the human enzyme. Cells transfected with the wild-type or mutant constructs were equally sensitive to the DHFR directed inhibitors methotrexate and trimetrexate.
Purification of Pro-254 Variants. To determine the effects of amino acid substitutions at position 254, proline was substituted with residues that represent various classes of amino acids, including leucine, glycine, phenylalanine, serine, and aspartic acid. With the exception of leucine, all enzymes complemented the growth of TS-deficient 2913 bacterial cells and constituted about 15% soluble protein. The P254L enzyme was not present in cell-free extracts but precipitated presumably into inclusion bodies; only inactive protein was recovered in the cell sonicates (data not shown). Wild-type and the remaining four variants were isolated to Ͼ90% purity. In vitro stability studies using 1 M purified enzyme and 50 M dUMP showed that, with the exception of glycine, the variants were less stable at 37°C than wild-type ecTS (data not shown). Whereas the half-life of wild-type ecTS was 90 min, the half-life of P254F, P254S, and P254D were approximately 50 min.
Steady-State Kinetic Constants. Values of K m for dUMP and CH 2 H 4 PteGlu, k cat and catalytic efficiencies (measured as k cat /K m ) are shown in Table 1 . The values for k cat and K m(dUMP) are similar among the enzymes, with P254D having the greatest variance from the wild-type value for both k cat and K m(dUMP) , but only by factors of 1.5 and 2.8, respectively. P254G, P254F, and P254S enzymes have K m(CH2H4PteGlu) values similar to the wild-type enzyme, whereas that for the P254D enzyme is Ͼ10-fold higher. Although the catalytic efficiencies of P254G, P254F, and P254S are similar to the wild-type enzyme, the decrease in k cat and increase in K m(CH2H4PteGlu) for P254D lowers the catalytic efficiency of this enzyme by approximately 15-fold.
Transient State Kinetic Constants-dUMP Binary Complex Formation. Because the values of K m depend on several rate constants, specific values that govern individual 
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at ASPET Journals on October 28, 2017 molpharm.aspetjournals.org steps along the catalytic pathway were determined. For ecTS the binding of dUMP is a simple bimolecular association reaction opposed by a unimolecular dissociation reaction. The binding of dUMP causes quenching of intrinsic protein fluorescence, the rate of which can be used to determine k on and k off values using the relationship k obs ϭ k on [dUMP] ϩ k off (Spencer et al., 1997) . Table 2 PteGlu and E ϭ ecTS⅐dUMP and P ϭ product of reaction (Spencer et al., 1997) .
K d is the dissociation constant for the initial binding of CH 2 H 4 PteGlu, k iso and k r,iso are the first-order rate constants governing the isomerization or interconversion of EL to EL*, and k chem is the rate constant governing the chemical conversion of substrates to products. On mixing of CH 2 H 4 PteGlu with ecTS ⅐ dUMP, a decrease in fluorescence is observed, the rate of which is hyperbolically dependent on the concentration of CH 2 H 4 PteGlu (Fig. 3) . For wild-type ecTS, the dependence of the observed rate on CH 2 H 4 PteGlu concentration is described by (Spencer et al., 1997) , which allows for the determination of K d , k iso , k r,iso and k chem , the values of which are reported in Table 3 . Similar to wild-type ecTS, the dependence of k obs on CH 2 H 4 PteGlu concentration is hyperbolic for P254F (data is omitted from Fig. 3 for clarity) but the affinity of the initial binding of CH 2 H 4 PteGlu is approximately 2-fold lower compared with wild-type ecTS and, because of a decrease in the rate governing the forward isomerization, almost 5-fold lower after protein isomerization (Table 3) . Interestingly, k obs for P254S does not show the hyperbolic dependence on CH 2 H 4 PteGlu concentration, suggesting that the affinity of ligand is not increased after binding and that the isomerization reaction is not significant for this variant. The binding of CH 2 H 4 PteGlu to P254S can be described by a bimolecular association followed by a unimolecular dissociation. The dependence of k obs on CH 2 H 4 PteGlu concentration can, therefore, be described by k obs ϭ k on [CH 2 H 4 PteGlu] ϩ k off and K d as k off /k on (Table 3) . Similar to P254S, P254D does not appear to show hyperbolic dependence of k obs on CH 2 H 4 PteGlu concentration. However, the K d value for this variant is very high, and the curvature may not be apparent at the ligand concentrations used. Differences in the dependence of k obs as a function of ligand concentration clearly indicate that substitutions at position 254 in ecTS affect cosubstrate binding as well as the ability of the variant enzymes to undergo isomerization after ligand binding.
Binary Complex Formation between FdUMP and Enzyme. Because a P303L mutation of human TS was identified in a FdUrd resistant cell line, rate constants governing FdUMP binary complex formation for the P254D enzyme were determined. Although the k on and k off values for dUMP Fig. 3 . Dependence of k obs on the concentration of CH 2 H 4 PteGlu for wild-type (diamonds), P254S (squares), and P254D ecTS (circles). Final enzyme and dUMP concentrations were 2 and 500 M, respectively. Refer to Table 3 for values obtained from the individual fits. On mixing AG337 with ecTS ⅐ dUMP, the intrinsic enzyme fluorescence is quenched. The rate of quenching is best described by a two-exponential equation. The observed rate of the first exponential is linearly dependent on ligand concentration, indicating that this process represents ligand binding. Values of k on and k off obtained from the linear fit of k obs with the concentration of AG337 are shown in Table 4 . The observed rate of the second exponential is not dependent on ligand concentration and has a value of approximately 40 s Ϫ1 , indicating that a conformational change occurs on AG337 binding. The binding of AG337 to the P254D enzyme is best described by a single exponential, and the observed rate of binding is linearly dependent on the concentration of AG337, which was used to calculate values of k on and k off ( Table 4) . The values of k on for AG337 binding to wild-type ecTS and to the P254D enzyme are similar, but the value of k off is approximately 7-fold higher for P254D, increasing the value of K d Ͼ7-fold (Table 4) .
Affinity of TS-Targeted Inhibitors and the Ability to Confer Drug Resistance. Compared with human TS, wildtype ecTS has higher K i values for raltitrexed and AG337 but a similar K i value for BW1843U89, which is consistent with previously reported results (Jackson et al., 1993) . The P254S and P254F mutants and wild-type ecTS have similar K i values for these three inhibitors. However, K i values are drastically increased for P254D, the greatest increase is observed with raltitrexed (Ͼ10-fold compared with wild-type ecTS and Ͼ100-fold compared with human TS) (Fig. 4A) . P254D was cloned into the HaMSV retroviral vector and transfected into the TS Ϫ cell line RJK88.13, and transformants were selected by removing thymidine from the growth media. Compared with cells transfected with either human TS or wild-type ecTS at similar enzyme levels (1.5 Ϯ 0.3 pmol bound FdUMP/mg of protein), P254D conferred the greatest resistance to raltitrexed (Fig. 4B) .
Crystallographic Data Measurement and Refinement. Steady-state kinetic and thermodynamic properties of P254S are virtually unchanged when compared with the wild-type enzyme. However, this mutation appears to affect ligand-induced isomerization. In an effort to better understand the effects of this mutation, high resolution data were collected from crystals of P254S to 100% completion with a mosaic spread of 0.37°and an R symm of 12%. The detailed collection strategy is summarized in Table 5 . The completeness is also 100% in the highest resolution shell, 1.55 to 1.50, with 4008 reflections having I Ͼ 2(I). The low resolution set was 96.7% complete to 2.10 Å with an R symm of 10%. The data were merged after rejecting intensity-saturated and weak reflections to give a 99.9% complete set of data to 1.50 Å. Merging of the two data sets yielded an R merge of 6.6 and 91.1% of the reflections having I/(I) Ͼ 2. After several rounds of refinement and modeling, the 2F o Ϫ F c electron density map was superb; it revealed holes in aromatic and proline rings, and a bulge of density for every carbonyl group. However, electron density was missing for a few side chains, especially residues 19-22 at the ␤-bend located between helix A and strand I, which are partially disordered. The data were refined to a final R-factor of 22% and has been deposited at the Protein Data Bank as entry 1qqq. Figure 5 shows that the effects of the P254S mutation are local and that the most significant difference between the wild-type enzyme and P254S is a 40 o rotation of the carbonyl plane of Asp-253. An ion pair is then capable of forming between Asp-253 and Arg-225. Although the positioning of the final four C-terminal residues (261-264) of P254S is slightly shifted compared with the wild-type enzyme, residues 257-260 are virtually unchanged.
Discussion
Clinical trials that introduce chemoprotecting genes into hematopoietic cells are aimed at protecting the recipient from the myelosuppressive side effects of chemotherapy (O'Shaughnessy et al., 1994; Hesdorffer et al., 1994; Deisseroth et al., 1996) . Transfer of genes encoding MDR-1 and DHFR have advanced to clinical trials and are model systems for the study of retroviral transfer of genes that confer drug resistance (Hock and Miller, 1986; Flasshove et al., 1995;  May et al., 1996) . Because dose-limiting toxicities associated with inhibitors of TS are myelosuppression and mucositis, we have been investigating gene transfer of drug-resistant variants of TS. Previously we showed that human and ecTS can be transferred using recombinant retroviruses and that retroviral gene transfer of the human TS Y33H variant conferred resistance to FdUrd and AG337. However, the degree of resistance was only 3-to 5-fold relative to nontransduced cells (Fantz et al., 1998) . It is, therefore, necessary to identify additional variants that confer greater drug resistance. Recently, Bertino and colleagues identified drug-resistant variants of human TS using ethyl methanesulfonate to generate random mutants. Two variants were identified, D49G and G52S, that had catalytic efficiencies similar to the wildtype enzyme and that conferred resistance to AG337 and FdUrd but not to raltitrexed or BW1843U89 (Tong et al., 1998a) . Resistance to raltitrexed and BW1843U89 was achieved using site-directed mutagenesis to target residues (Ile-108 and Phe-225) within the folate binding site, (Tong et al., 1998b) . Although the catalytic efficiency (k cat /K m for CH 2 H 4 PteGlu) of the variant I108A is Ͼ200-fold lower than the wild-type enzyme, this variant conferred antifolate resistance to transfected mouse bone marrow cells. Landis and Loeb used random sequence mutagenesis to target 13 active site residues of human TS and identified a triple mutant, A197V/L198I/C199F, that had a FdUMP dissociation constant 20-fold higher than values obtained for wild-type human TS, without severely compromising catalytic efficiency (Landis and Loeb, 1998) . By adapting colon tumor cell lines to increasing concentrations of FdUrd, we identified a P303L variant that conferred Ͼ20-fold resistance to both FdUrd and AG337, 4-fold resistance to raltitrexed, and 3-fold to BW1843U89 (Kitchens et al., 1999) .
Because a detailed kinetic scheme has been determined for ecTS and because ecTS is, compared with human TS, intrinsically resistant to several TS inhibitors (Jackson et al., 1993; Spencer et al., 1997) , the corresponding Pro to Leu substitution, along with phenylalanine, serine, glycine, and aspartic acid, were introduced at residue 254 of ecTS. Similar to human P303L, the P254L enzyme conferred resistance to FdUrd and raltitrexed. However, the degree of resistance was substantially greater (i.e., Ͼ100-fold) for the ecTS variant.
The observations that P303L in human TS is less stable than wild-type human TS, that the P254L enzyme of E. coli is sequestered into inclusion bodies, and that the purified Pro-254 mutant enzymes have decreased stability in vitro indicate that tertiary structural changes occur as a result of these mutations. With respect to kinetic and thermodynamic constants, the most drastic affects of mutations at residue 254 are impaired protein isomerization and diminished CH 2 H 4 PteGlu affinity. For instance, the affinity of the initial Fig. 4 . A, K i values determined for wild-type, P254F, P254S, and P254D relative to K i values obtained for human TS; B, HaMSV retroviral vectors encoding human TS, wild-type ecTS, or P254D were transfected into RJK88.13 cells, transformants were selected in media lacking thymidine, and IC 50 values were obtained for raltitrexed as described in Fig. 2 . Error bars represent the standard deviation of the IC 50 value obtained for wild-type ecTS or P254D relative to the IC 50 value obtained for human TS in three individual experiments. Proline 254 is located 11 amino acids from the C terminus of ecTS. Crystal structures show that this residue is located at a bend that directs the C-terminal residues toward the active site. On ternary complex formation, the terminal 4 -5 residues of the enzyme undergo dramatic positional changes (Montfort et al., 1990; Matthews et al., 1990) . Several studies have shown that the C terminus is critical to enzyme function (Perry et al., 1993; Carreras and Santi, 1995; Spencer et al., 1997) . It can be speculated that mutations at residue 254 affect ligand binding and conformational isomerization by perturbing the movement of the C-terminal residues. However, the structure of P254S suggests a different mechanism. Our modeling indicates that larger side chains at 254 must be accommodated by a movement of the side chain of Arg-48. Although located on the surface and apparently not directly involved in catalysis, ligand binding, or dimer formation, Arg-48 is a highly conserved residue. This strongly suggests that its charge is essential for the proper functioning of TS. Larger side chains at 254 will push the guanidinium moiety of Arg-48 into the solvent region, and the effect of its charge will be attenuated by the high dielectric constant of water. This hypothesis will be tested further by studying mutants of Arg-48.
In addition, the replacement of Pro-254 with serine (and presumably other amino acids) relaxes constraints on the conformation of the main chain and causes a rotation of the carbonyl plane of Asp-253 by about 40° (Fig. 5 ). This is accompanied by a shift of the side chain of Asp-253, which forms an ion pair with Arg-225. This change is local and does not propagate toward the C terminus. A least-squares superposition of the high resolution structures of wild-type TS and P254S does not show significant conformational changes in the 255-264 region. It should be noted, however, that the structure of ternary inhibitory complex TS/dUMP/CB3717 (Montfort et al., 1990; Protein Data Bank entry, 2tsc) in the closed conformation also shows a shift in the position of the side chain of Asp-253. There is no obvious link between the conformational change at the C terminus, which involves residues 261-264, and the shift at 253 as the residues 254 -260 are not affected by the formation of the closed conformation. These observations clearly indicate some role of Pro-254 in the transition between the open and close conformations.
Variants of ecTS at residue 254 can potentially be used as modulators of TS-directed chemotherapy and may prove useful in providing proof-of-principle results in animal studies to show the applicability of TS as a chemoprotecting agent. Mutations at residue 254 cause impaired binding of TStargeted antifolates, while maintaining catalytic efficiencies similar to the wild-type enzyme. The variant P254D conferred substantial resistance against raltitrexed and, of the variants studied, exhibited the most favorable properties for use in future gene transfer experiments. However, because the bacterial enzyme is being used, its applications may be limited due to the potential of immune responses.
